Abagyl(Metronidazole) Iv 0.5%

Abagyl(Metronidazole) Iv 0.5%

ABAGYL (Metronidazole) IV 0.5% is a sterile intravenous infusion used to treat and prevent serious infections caused by anaerobic bacteria and certain parasites. Each 100 ml contains 500 mg of metronidazole, making it a reliable treatment for deep-seated infections such as intra-abdominal abscesses, pelvic infections, bone infections, central nervous system infections, and post-operative complications.

It is also widely used to prevent infections during abdominal and gynecological surgery. ABAGYL must be administered only by trained healthcare professionals in hospitals or clinical settings.

Key Uses of ABAGYL Metronidazole IV 0.5%

• Treatment of severe anaerobic bacterial infections

• Management of abdominal and pelvic infections

• Treatment of bone and joint infections

• Prevention of infections during abdominal or gynecological surgery

• Management of sepsis and bloodstream infections caused by anaerobes

• Treatment of CNS infections such as brain abscesses

Mechanism of Action

Metronidazole destroys anaerobic bacteria and certain protozoa by interfering with their DNA structure and inhibiting protein synthesis, stopping the infection at its source.

Administration & Dosage

• Route: Intravenous infusion (IV drip)

• Strength: 500 mg per 100 ml (0.5% w/v solution)

• Infusion: Must be given as a slow IV drip

• Dosage: Determined by the treating physician based on infection severity and patient condition

• Not for self-administration

 Important Safety Information

• Do not consume alcohol or products containing propylene glycol during treatment or for 3 days after the last dose

• Monitor for allergic reactions (swelling, difficulty breathing)

• May cause dizziness, metallic taste, nausea, or abdominal discomfort

• Serious side effects include nerve problems, seizures, confusion, liver issues—seek urgent medical attention

• Use with caution in patients with liver disease, kidney disease, blood disorders, or neurological conditions

• Not recommended during the first trimester of pregnancy unless medically necessary

• Animal studies show potential carcinogenic effects—use only when prescribed